MXPA00009058A - Method of reducing cellulite in mammalian skin - Google Patents
Method of reducing cellulite in mammalian skinInfo
- Publication number
- MXPA00009058A MXPA00009058A MXPA/A/2000/009058A MXPA00009058A MXPA00009058A MX PA00009058 A MXPA00009058 A MX PA00009058A MX PA00009058 A MXPA00009058 A MX PA00009058A MX PA00009058 A MXPA00009058 A MX PA00009058A
- Authority
- MX
- Mexico
- Prior art keywords
- mixtures
- group
- composition
- skin
- further characterized
- Prior art date
Links
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 21
- 230000036232 cellulite Effects 0.000 title claims abstract description 21
- 210000003491 Skin Anatomy 0.000 title claims description 41
- 239000000203 mixture Substances 0.000 claims abstract description 70
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 24
- 239000011570 nicotinamide Substances 0.000 claims abstract description 24
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 21
- 229940053487 Niacinamide Drugs 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 150000001261 hydroxy acids Chemical class 0.000 claims description 5
- 206010007882 Cellulitis Diseases 0.000 claims description 4
- 229960000278 Theophylline Drugs 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 230000000475 sunscreen Effects 0.000 claims description 4
- 239000000516 sunscreening agent Substances 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 206010040844 Skin exfoliation Diseases 0.000 claims description 3
- 229960004559 Theobromine Drugs 0.000 claims description 3
- 230000000111 anti-oxidant Effects 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 claims description 3
- 230000035618 desquamation Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N 2-phenyl-3H-benzimidazole-5-sulfonic acid Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
- 229960001295 Tocopherol Drugs 0.000 claims description 2
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 claims description 2
- 229960000655 ensulizole Drugs 0.000 claims description 2
- 229960000601 octocrylene Drugs 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229960000342 retinol acetate Drugs 0.000 claims description 2
- 235000019173 retinyl acetate Nutrition 0.000 claims description 2
- 239000011770 retinyl acetate Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229930003799 tocopherols Natural products 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 230000000699 topical Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 229940020899 hematological Enzymes Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 240000001432 Calendula officinalis Species 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 4
- 210000002615 Epidermis Anatomy 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 229940101267 Panthenol Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 235000020957 pantothenol Nutrition 0.000 description 4
- 239000011619 pantothenol Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229940095074 Cyclic AMP Drugs 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- WSDISUOETYTPRL-UHFFFAOYSA-N DMDM hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- 229940093629 ISOPROPYL ISOSTEARATE Drugs 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 235000002912 Salvia officinalis Nutrition 0.000 description 3
- 229940042585 Tocopherol Acetate Drugs 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- -1 but not limited to Substances 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 101710031992 pRL90232 Proteins 0.000 description 3
- 101710035540 plaa2 Proteins 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000002020 sage Nutrition 0.000 description 3
- 239000002884 skin cream Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- 210000001217 Buttocks Anatomy 0.000 description 2
- 235000003880 Calendula Nutrition 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- 229960001631 Carbomer Drugs 0.000 description 2
- 241001503987 Clematis vitalba Species 0.000 description 2
- 210000004207 Dermis Anatomy 0.000 description 2
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 2
- 240000008526 Hypericum perforatum Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229940039717 Lanolin Drugs 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000002141 Pellagra Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 241001529742 Rosmarinus Species 0.000 description 2
- 241000605385 Ruscus Species 0.000 description 2
- 240000000353 Ruscus aculeatus Species 0.000 description 2
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 2
- 241001530490 Salvia rosmarinus Species 0.000 description 2
- 235000002197 St. John’s wort Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940053550 agents used for ADHD and nootropics psychostimulants Xanthine derivatives Drugs 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000005035 ginseng Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229940083747 low-ceiling diuretics Xanthine derivatives Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 108010032809 mucopolysaccharidase Proteins 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 2
- 239000001296 salvia officinalis l. Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N trans-Retinyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- CDMGNVWZXRKJNS-UHFFFAOYSA-N 2-benzylphenol Chemical compound OC1=CC=CC=C1CC1=CC=CC=C1 CDMGNVWZXRKJNS-UHFFFAOYSA-N 0.000 description 1
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methylpentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 Adenosine phosphate Drugs 0.000 description 1
- 229940024606 Amino Acids Drugs 0.000 description 1
- 229960003556 Aminophylline Drugs 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 229960005274 Benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 229940048851 CETYL RICINOLEATE Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 Camphor Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000385 Dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N Dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241001300514 Eua Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000001974 Hyaluronidase Human genes 0.000 description 1
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N Iodopropynyl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229940031674 LAURETH-7 Drugs 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229940100460 PEG-100 Stearate Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N Pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 206010037855 Rash erythematous Diseases 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 210000004927 Skin cells Anatomy 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 210000004003 Subcutaneous Fat Anatomy 0.000 description 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- DMMXZLMYEUEJFT-UHFFFAOYSA-N ethyl 16-methylheptadecanoate Chemical compound CCOC(=O)CCCCCCCCCCCCCCC(C)C DMMXZLMYEUEJFT-UHFFFAOYSA-N 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000002366 lipolytic Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 229940093883 pramoxine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000002227 vasoactive Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229950004578 vitamin A palmitate Drugs 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
The present invention relates to a method for combating cellulite or reducing localized fatty excesses which comprises administering to a person having cellulite or localized fatty excesses a body slimming amount of a composition containing niacinamide.
Description
METHOD TO REDUCE CELLULITE IN MAMMALIAN SKIN
FIELD OF THE INVENTION
The present invention relates to a method for combating cellulite or reducing localized fat excesses comprising the administration of a quantity for body thinning of a composition containing niacinamide to a person having cellulite or localized excess fat.
BACKGROUND OF THE INVENTION
Suffering from cellulitis is a difficult problem that causes emotional and psychological upheaval in many women. Cellulitis mainly affects the thighs and buttocks but can also occur in the stomach and upper arms. Frequently, cellulite presents an appearance of crumbly orange peel, not perceptible. Clinically, ceiulitis manifests a variety of symptoms including thinning of the epidermis, reduction and decomposition of the microvasculature that leads to subdermal fluid accumulations, and subdermal agglomerations of fatty tissue. It has been observed that polymeric proteoglycans are a major component of these agglomerations.
To release these agglomerations and trapped fatty fluids, the local application of enzymes or compositions containing enzymes has been proposed because the enzymes are capable of depolymerizing the proteoglycans. These enzymes include mucopolysaccharidases and, in particular, hyaluronidase, thiomucase and a-mucase. Among the methods to stimulate lipolysis, the most commonly known and used is that which inhibits phosphodiesterase in order to avoid or at least limit the degree of degradation of cyclic AMP. In effect, phosphodiesterase destroys cyclic AMP by transforming it into 5 'AMP so that it can not function as a lipolysis activator. It is then important to inhibit the activity of the phosphodiesterase so that a high amount of cyclic AMP is present at the level of the adipocytes thus stimulating the lipolytic activity. Various representative phosphodiesterase inhibitors, which are known as thinning agents, include in particular xanthine derivatives and particularly theophylline, caffeine and theobromine. Furthermore, it is known to use certain oil-soluble plant extracts which, according to a different mechanism, can act as a thinning agent. For example, in the patent of E.U.A. No. 4,795,638 discloses a thermo-thinning cosmetic composition containing an oil-soluble plant extract having a thinning action. Representative examples of these oil-soluble plant extracts are vegetable extracts that include mainly, those of climber (Hederá Helix), arnica (Arnica Montana), rosemary (Rosmarinus Officinalis N), calendula (Calendula officinalis), sage (Salvia officinalis) N), ginseng (Panax Ginseng), (Hypericum Perforatum), ruscus (Ruscus aculeatus), ulmaria (Fílapendula ulmaria L) and ortosifon (Ortosifon Stamincus Benth), as well as mixtures of these plant extracts. Regardless of such descriptions, there is a need to obtain improved compositions for reducing cellulite in mammalian skin. The present inventor has found that skin care compositions containing niacynamide help reduce cellulite in the skin. Also, it is an object of the present invention to provide methods for reducing cellulite in mammalian skin. Another object of the present invention is to provide skin compositions, which are applied topically to reduce cellulite, and which contain a safe and effective amount of niacinamide. These and other objects will be apparent from the following detailed description.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to methods of treatment and / or prevention of cellulite by administering a safe and effective amount of a composition for skin care comprising: (a) a safe and effective amount of niacynamide; and (b) a dermatologically acceptable vehicle for niacinamide. The present invention also relates to articles of manufacture comprising a composition for skin care comprising from about 0.1% to about 40%, by weight, of niacinamide in a package for said composition for skin care in together with information and / or instructions on the use of niacinamide to treat cellulite. Unless otherwise indicated, all percentages and ratios used herein are by weight of the total composition. All percentages by weight, unless otherwise indicated, are on a weight basis of the active compounds. All measurements made are at approximately 25 ° C, unless otherwise indicated. The term "safe and effective amount" as used herein means an amount of a compound or composition sufficient to induce significantly a positive benefit, preferably a positive skin appearance or sensation benefit, including independently the benefits described herein. , but low enough to avoid serious side effects, that is, provide a reasonable ratio of benefit to risk, within the scope of the solid judgment of the person skilled in the art.
DETAILED DESCRIPTION OF THE INVENTION
The compositions used in the present invention may comprise, consist of, or consist essentially of the essential elements and limitations of the invention described herein, as well as of any of the additional or optional ingredients, components or limitations described in the present invention.
ESSENTIAL COMPONENTS
Niacinamide Nicotinic acid and niacinamide (nicotinamide or nicotinic acid amide) are water-soluble vitamins, whose physiologically active forms of nimotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) play a major role as coenzymes in a variety of important metabolic reactions. Nicotinic acid is an essential dietary constituent, which itself is lacking leading to pellagra, a condition characterized by an erythematous skin rash as well as gastrointestinal and neurological symptoms. Nicotinic acid and niacinamide have been used routinely to treat pellagra because they are therapeutic. Nicotinic acid as well as niacynamide are available from a variety of pharmaceutical houses such as Armor Pharmaceutical Company located in Phoenix, Ariz .; Brown Pharmaceutical Company Inc. located in Los Angeles, Calif .; and Keith Pharmaceutical Inc. located in Miami, Fia. Without trying to be limited by theory, it is believed that niacinamide reduces cellulite by several mechanisms. Niacinamide stimulates epidermal cells and will therefore thicken the tissue to counteract the thinning of the epidermis that is associated with cellulite. These compounds are also vasoactive (stimulate blood flow) and therefore improve the reduction in microvascularization associated with cellulitis. Additionally, niacinamide stimulates metabolism in skin cells in general (e.g., epidermis, dermis, subcutaneous fat) that increases the cellular production of enzymes for removal of fatty tissue agglomerations and / or proteoglycans. The niacynamide is preferably present in the compositions used in the present invention in concentrations of from about 0.1% to about 50%, most preferably from about 1% to about 30%, and still most preferably from about 1% to about 20% , most preferably from about 1% to about 10%.
Vehicle The compositions used in the present invention also comprise a dermatologically acceptable vehicle. The phrase "dermatologically acceptable vehicle", as used herein, means that the vehicle is suitable for topical application on the skin, has suitable aesthetic properties, is compatible with the active ingredients of the present invention and with any other component, and It will not cause any safety or toxicity concerns. A safe and effective amount of a vehicle is from about 50% to about 99.99%, preferably from about 99.9% to about 80%, most preferably from about 98% to about 90%, more preferably from about 95% to about 90% of the composition. The vehicle can have a wide variety of forms. For example, emulsion vehicles, including, but not limited to, oil in water emulsions, water in oil, water in oil in water, and oil in water in silicone are useful herein. These emulsions can cover a wide range of viscosities, for example, from about 100 cps to about 200,000 cps. These emulsions can also be supplied in the form of sprays using either mechanical pumping containers or pressurized aerosol containers using conventional propellants. These vehicles can also be supplied in the form of a mousse. Other suitable topical vehicles include anhydrous liquid solvents such as oils, alcohols, and silicones (e.g., mineral oil, ethanol, isopropanol, dimeticon, cyclomethicone, and the like); liquid solvents of individual phase of aqueous base (for example, systems of hydra-alcoholic solvents); and thickened versions of these anhydrous and water-based individual phase solvents (eg, wherein the viscosity of the solvent has been increased to form a solid or semi-solid by the addition of gums, resins, waxes, polymers, suitable salts and the like) . Examples of topical vehicle systems useful in the present invention are described in the following four references, all of which are hereby incorporated by reference in their entirety: "Sun Products Formulary" Cosmetics & Toiletries, vol. 105, pp. 122-139 (December 1990); "Sun Products Formulary", Cosmetics & Toíletries, vol. 102, pp. 117-136 (March 1987); patent of E.U.A. No. 4,960,764 to Figueroa et al., Issued October 2, 1990 and patent of E.U.A. No. 4,254,105 to Fukuda et al, issued March 3, 1981. The vehicles of the present invention may comprise from about 50% to about 99% by weight of the compositions of the present invention, preferably from about 75% to about 99. % and more preferably around 85% to about 95%. Preferred cosmetic and / or pharmaceutically acceptable topical vehicles include hydro-alcoholic systems and oil-in-water emulsions. When the vehicle is a hydra-alcoholic system, the vehicle may comprise about 0% to about 99% ethanol, isopropanol or mixtures thereof, and about 1% to about 99% water. More preferred is a vehicle comprising about 5% to about 60% ethanol, isopropanol or mixtures thereof, and about 40% to about 95% water. A vehicle comprising about 20% to about 50% ethanol, isopropanol or mixtures thereof, and about 50% to about 80% water is especially preferred. When the vehicle is an oil-in-water emulsion, the vehicle can include any of the common excipient ingredients for preparing these emulsions. A more detailed description of suitable vehicles is found in the US patent. 5,605,894 to Blank et al., And in PCT application WO 97/39733, published October 30, 1997, to Oblong et al., Both are incorporated herein by reference in their entirety.
Optional Components The compositions used in the present invention may optionally comprise additional materials including slimming agents as well as additional active ingredients useful in providing cellulite control. Among these agents are phosphodiesterase inhibitors (eg, xanthine derivatives such as theophylline, caffeine, theobromine or salts thereof such as aminophylline) and certain oil-soluble plant extracts, including, in particular, those of climber (Hederá Helix), arnica (Arnica Montana), rosemary (Rosmarinus Officinalis N), calendula (Calendula officinalis), sage (Salvia officinaalis N), ginseng (Panax Ginseng), (Hypericum Perforatum), ruscus (Ruscus aculeatus), ulmaria (Fílapendula ulmaria L) and ortosífon (Ortosifon Stamíncus Benth), as well as mixtures of these extracts of vegetables, all the previous ones described in the patent of EUA 4,795,638, incorporated herein by reference. Herbal and / or botanical extracts such as those described in the U.S. Patents are also useful. 5,705,170 and 5,667,793 both incorporated herein by reference. Mixtures of any of the above additional materials may also be used. The compositions used in the present invention may optionally comprise additional skin actives. Non-limiting examples of said active ingredients for skin include hydroxy acids such as salicylic acid; desquamation agents such as zwitterionic surfactants; sunscreens such as 2-ethylhexyl p-methoxycinnamate, 4,4'-t-butyl methoxydibenzoyl-methane, octocrylene, phenylbenzimidazole sulfonic acid; sun blockers such as zinc oxide and titanium dioxide; anti-inflammatory agents; corticosteroids such as hydrocortisone, methylprednisolone, dexamethasone, triamcinolone acetconide, and deoxametasone; anesthetics such as benzocaine, dyclonine, lidocaine and tetracaine; antituritics such as camphor, menthol, oat (colloidal), pramoxine, benzyl alcohol, phenol and resorcinol; antioxidants / radical scavengers such as tocopherol and esters thereof; chelators; retinoids such as retinol, retinyl palmitate, retinyl acetate, retinyl propionate and retinal; hydroxy acids such as glycolic acid; keto acids such as pyruvic acid; N-acetyl-L-cysteine and derivatives thereof; benzofuran derivatives; and skin protectors. Mixtures of any of the active ingredients for skin mentioned above can also be used. A more detailed description of these assets is found in the patent of E.U.A. 5,605,894 to Blank et al (previously incorporated by reference). Preferred skin active ingredients include hydroxy acids such as salicylic acid, sunscreens, antioxidants and mixtures thereof. Other conventional skin care product additives may also be included in the compositions of the present invention. For example, urea, guanidine, glycerol, petrolatum, mineral oil, sugar esters and polyesters, polyolefins, methyl stearate, ethyl isostearate, cetyl ricinoleate, sononyl sononanoate, sohexadecane, lanolin, lanolin esters, cholesterol , carboxylic acid / pyrrolidone salt (PCA), trimethylglycine (betaine), tranexamic acid, amino acids (eg, serine, alanine), panthenol and its derivatives, collagen, hyaluronic acid, elastin, hydrolysates, rose oil, jojoba oil , epidermal growth factor, soy saponins, mucopolysaccharides and mixtures thereof. Other suitable skin additives or active ingredients are described in greater detail in the PCT application WO 97/39733, published October 30, 1997, to Oblong et al., And incorporated herein by reference in its entirety.
Preparation of skin care compositions The compositions that are used in the present invention are generally prepared by conventional methods such as those known in the art of making topical compositions. Such methods typically include mixing the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, applying vacuum and the like. Non-limiting examples of the product form can be gel, emulsion, lotion, cream, ointment, solution, liquid, etc.
Methods for the treatment of cellulite The methods of the present invention are useful for treating or preventing cellulite, especially in the subcutaneous tissues, dermis and epidermis of mammalian skin. The methods of the present invention are to apply topically to the skin an effective amount of the skin care composition herein. The amount of the composition to be applied, the frequency of application and the period of use will vary widely depending on the level of niacinamide and / or the other components of a certain composition, and the degree of cellulite fading desired. The skin care compositions used in the present invention are chronically applied to the skin. By "chronic topical application" is meant continuous topical application of the composition over an extended period during the subject's life, preferably over a period of at least about one week, preferably over a period of about two weeks, most preferably during a period of at least about one month, still most preferably about three months, even most preferably at least about six months and more preferably still at least about one year. Although the benefits can be obtained after several periods of maximum use (for example, five, ten or twenty years), it is preferred that the chronic application continue throughout the life of the subject to maintain and / or increase the benefits achieved. Applications will typically be in the order of one to four times a day during such extended periods, however application rates may be more than four times a day, especially on areas prone to agglomerations of fat and water such as thighs and the buttocks. A wide range of amounts of the compositions of the present invention can be employed to provide a benefit of skin appearance and / or sensation. The amounts of the present compositions that are typically applied per application are, in milligrams of composition per square centimeter of skin, about 0.1 mg / cm2 to about 10 mg / cm2. A particularly useful application amount is approximately 2 mg / cm2. The method for treating cellulite is preferably carried out by applying a composition in the form of a lotion, gel, cosmetic or the like for the skin that is intended to be left on the skin for aesthetic, prophylactic, therapeutic, and other benefits (i.e. a "non-rinsing" composition). After applying the composition to the skin, it is preferably left on the skin for a period of at least 15 minutes, most preferably at least about 30 minutes, still more preferably at least about 1 hour, and preferably for at least several hours, for example, up to about 12 hours. Another approach to ensure continuous exposure of the skin to at least a minimum level of niacinamide is to apply the compound by the use of a patch. This approach is particularly useful for problematic areas of the skin that require more intensive treatment. The patch may be obstructive, semi-obstructive or non-obstructive. The niacynamide composition may be contained in the patch or applied to the skin prior to the application of the patch. The patch may also include additional active agents such as chemical initiators for exothermic reactions such as those described in the PCT application WO 9701313 to Burkett et al. The patch is preferably applied overnight as a form of nocturnal therapy.
EXAMPLES
The following examples describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and should not be considered as limitations of the present invention, since many variations thereto are possible without departing from the spirit and scope thereof.
EXAMPLE 1
The following is an example of a skin cream incorporating the compositions of the present invention. The compositions are formed by combining and mixing the ingredients of each column using conventional technology and applying them to the skin of about 0.5 g to about 50 g.
Ingredient% by weight Glycerin 6,933 Niacínamida 15,000 Permetil 101A1 3,000 Sepigel2 2,500 Q2-14033 2,000 Isopropyl isostearate 1,330 Arlatone 21214 1,000 Cetyl alcohol CO-1695 0.720 SEAC cottonate »5 0.670 Tocopherol acetate 0.500 Panthenol 0.500 Adol 626 0.480 Titanium dioxide-kobo 0.400 Sodium hydroxide 50% 0.0125 Aqueous Fiery 57 0.150 Disodium EDTA 0.100 Glydant Plus8 0.100 Myrj 599 0.100 Emersol 13210 0.100 Color 0.00165 Purified water cbp 100
EXAMPLE 2
The following is an example of a skin cream incorporating the compositions of the present invention. The compositions are formed by combining and mixing the ingredients of each column using conventional technology and applying them to the skin of about 0.5 g to about 50 g.
I nq network weight% Glycerin 6,933 Niacinamide 12,000 Permethyl 101 A1 3,000 Sepigel2 2,500 Q2-14033 2,000 Isopropyl isostearate 1,330 Arlateme 21214 1,000 Cetyl alcohol CO-1695 0.720 SEAC cottonate »5 0.670 Tocopherol acetate 0.500 Panthenol 0.500 Adol 626 0.480 Dioxide titanium-kobo 0.400 Sodium hydroxide 50% 0.0125 Aqueous Fiery 57 0.150 Disodium EDTA 0.100 Glydant Plus8 0.100 Myrj 599 0.100 Emersol 13210 0.100 Color 0.00165 Purified water cbp 100
EXAMPLE 3
The following is an example of a skin cream incorporating the compositions of the present invention. The compositions are formed by combining and mixing the ingredients of each column using conventional technology and applying them to the skin of about 0.5 g to about 50 g.
Ingredient% by weight Glycerin 6,933 Niacinamide 12,000 Permethyl 101 A1 4,000 Q2-14033 2,000 Isopropyl isostearate 1,330 Arlateme 21214 1,000 Cetyl alcohol CO-1695 0.720 SEAC cottonate5 0.670 Carbopol 95411 0.500 Tocopherol acetate 0.500 Panthenol 0.500 Adol 626 0.480 Titanium dioxide-kobo 0.400 Sodium hydroxide 50% 0.250 Aqueous Fiery 57 0.150 Disodium EDTA 0.100 Giydant Plus8 0.100 Myrj 599 0.100 Emersol 13210 0.100 Color 0.00165 Purified water cbp 100
1. Isohexadecane, Presperse Inc., South Plainfield, NJ 2. Polyacrylamide (y) C13-14 Isoparaffin (y) Laureth-7, Seppíc Corporation, Fairfield, NJ 3. dimethicone (y) dimethiconol, Dow Corning Corp., Midland, Ml 4 Sorbitan monostearate and Sucrococoate, ICI Americas Inc., Wilmington, DE 5. Fatty acid sucrose ester, Procter and Gamble, Cincinnati, OH 6. Stearyl alcohol, Procter and Gamble, Cincinnati, OH 7. Fiery 5 n / a , Procter and Gamble, Cincinnati, OH 8. DMDM Hydantoin (and) Iodopropynyl Butylcarbamate, Lonza Inc., Fairlawn, NJ 9. PEG-100 Stearate, ICI Americas Inc., Wilmington, DE 10. Stearic Acid, Henkel Corp., Kankakee, IL 11. Carbomer, BF Goodrich, Cleveland OH 12. Carbomer, BF Goodrich, Cleveland OH
Claims (9)
1. - A skin care composition for treating and / or preventing cellulitis in a mammal that has, or is prone to form cellulite, comprising: a) a safe and effective amount of niacinamide; and b) a dermatologically acceptable vehicle for the niacynamide.
2. The composition according to claim 1, further characterized in that the concentration of niacinamide is from 1% to 20%.
3. The composition according to any of the preceding claims, further characterized in that the niacinamide is substantially non-complex.
4. The composition according to any of the preceding claims, further characterized in that the composition comprises an additional active selected from the group consisting of phosphodiesterase inhibitors, oil-soluble plant extracts, herbal extracts, botanical extracts and mixtures thereof.
5. The composition according to any of the preceding claims, further characterized in that the additional active is a phosphodiesterase inhibitor selected from the group consisting of theophylline, caffeine, theobromine, salts thereof and mixtures thereof.
6. The composition according to any of the preceding claims, further characterized in that it comprises an additional skin active selected from the group consisting of hydroxy acids, desquamation agents, sunscreens, antioxidants, retinoids and mixtures thereof.
7. The composition according to any of the preceding claims, further characterized in that the hydroxy acid is salicylic acid; the desquamation agent is selected from the group consisting of zwitterionic surfactants and mixtures thereof; the sunblock is selected from the group consisting of zinc oxide, titanium dioxide and mixtures thereof; the sunscreen is selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, 4,4'-t-butyl methoxydibenzoyl-methane, phenylbenzimidazole sulfonic acid, octocrylene and mixtures thereof; the antioxidant is selected from the group consisting of tocopherol, esters thereof and mixture thereof; and the retinoid is selected from the group consisting of retinol, retinyl acetate, retinyl propionate and mixtures thereof.
8. The composition according to any of the preceding claims, further characterized in that the composition for skin care is contained within a patch or applied to the skin and covered by a patch.
9. An article of manufacture comprising a composition for skin care comprising from 0.1% to 40%, by weight, of niacinamide in a package for said composition for skin care.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/078,163 | 1998-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00009058A true MXPA00009058A (en) | 2001-07-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5962482A (en) | Method of reducing cellulite in mamalian skin | |
US5436230A (en) | Use of a growth factor in a slimming composition | |
EP1614430B1 (en) | Compositions containing anti-acne agents and the use thereof | |
CA2337772C (en) | Skin and tissue care and/or treatment agent | |
US8017138B2 (en) | Composition and method for treating skin | |
US7629371B2 (en) | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite | |
EP1077066A1 (en) | Preventives/remedies for skin diseases | |
US5728393A (en) | Process for combating adiposity and compositions which may be used for this purpose | |
US7189406B1 (en) | Composition and method for treating skin | |
EP3713583A1 (en) | Methods and compositions for treatment of skin | |
JP2002506821A (en) | How to treat skin irritation | |
EP1625844A1 (en) | The composition for external use by percutaneous administration | |
RU2199319C1 (en) | Compositions for cutaneous diseases healing | |
US20040170702A1 (en) | Method and composition for treating hypopigmentation of the hair and skin | |
KR20010041868A (en) | Skin moisturizing compositions | |
WO2003006009A1 (en) | Compositions for reducing or preventing cellulite in mammalian skin | |
US5128375A (en) | Keloid treating agent | |
WO1997046221A1 (en) | Cosmetic method for treating and preventing the signs of skin ageing | |
EP1752132A2 (en) | Skin cosmetic compositions | |
MXPA00009058A (en) | Method of reducing cellulite in mammalian skin | |
JPH09255551A (en) | Skin preparation for external use | |
CZ20002863A3 (en) | Cosmetic method for treating and/or prevention of cellulitis and industrial product | |
JP2002506804A (en) | Skin care composition | |
CN114246875A (en) | Anti-inflammatory and freckle-removing compound nicotinamide composition and application thereof | |
JPH0920640A (en) | External preparation for improving chapped skin |